2-氯-5-氟喹啉 | 455955-27-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 2-氯-5-氟喹啉
• 英文名称: 2-chloro-5-fluoroquinoline
• CAS: 455955-27-8
• 化学式: C₉H₅ClFN
• mdl: MFCD10001462
• 分子量: 181.597
• InChiKey: QGVJVNBPDLHVHV-UHFFFAOYSA-N

物化性质

• 沸点：
  271.3±20.0 °C(Predicted)
• 密度：
  1.366±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933499090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-氯-5-氟喹啉 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 乙二醇乙醚 、 乙醇 、 水 、 甲苯 为溶剂， 反应 30.0h， 生成
  参考文献：
  名称：

  带有氟，苯基和氟苯基取代的2-芳基喹啉配体的红色磷光双环金属铱配合物

  摘要：

  设计并合成了基于氟，苯基和氟苯基取代的2-芳基喹啉配体的红色磷光铱（III）配合物。为了研究其电致磷光性能，制造了具有以下结构的器件：氧化铟锡（ITO）/ 4,4'，4''-三[2-萘基（苯基）氨基]三苯胺（2-TNATA）/ 4,4 '-双[ N-（1-萘基）-N-苯氨基]联苯（NPB）/ 4,4'-双（N-咔唑基）-1,1'-联苯（CBP）：8％铱（III）络合物/ bathocuproine（BCP）/ tris（8-hydroxyquinolinato）铝（Alq 3）/ 8-羟基喹啉锂（Liq）/铝 使用这些材料的所有设备均显示出有效的红色发射。具体地，器件呈现的饱和红色发射具有最大亮度，外部量子效率，和14200 CD米发光效率-2，8.44％，和6.58光盘-1在20mA厘米-2，分别。该设备的CIE（x，y）坐标在12.0 V时为（0.67，0.33）。

  DOI：

  10.1002/chem.201504392
• 作为产物：
  描述：

  5-氨基喹啉 在 过氧乙酸 、 tetrafluoroboric acid 、 sodium nitrite 、 三氯氧磷 作用下， 以 氯仿 、 水 为溶剂， 反应 6.0h， 生成 2-氯-5-氟喹啉
  参考文献：
  名称：

  Synthesis of a fluorine-18-labelled derivative of 6-nitroquipazine, as a radioligand for the In vivo serotonin transporter imaging with PET

  摘要：

  Considerable efforts have been engaged in the design, synthesis and pharmacological characterization of radioligands for imaging the serotonin transporter, based on its implication in several neuropsychiatric diseases, Such as depression, anxiety and schizophrenia. In the 5-halo-6-nitroquipazine series, the fluoro derivative has been designed for positron emission tomography (PET). The corresponding 5-iodo-, 5-bromo- and 5-chloro N-Boc-protected quipazines as labelling precursors, as well as 5-fluoro-6-nitroquipazine as a reference compound have been synthesized. 5-[F-18]Fluoro-6-nitroquipazine has been radiolabelled with fluorine-18 (positron-emitting isotope, 109.8 min half-life) by nucleophilic aromatic substitution from the corresponding N-Boc protected 5-bromo- and 5-chloro-precursors using K[F-18]F-K-222 complex in DMSO by conventional heating (145degreesC, 2 min) or microwave activation (50 W, 30-45 s), followed by removal of the protective group with TFA. Typically, 15-25 mCi (5.5-9.2 GBq) of 5-[F-18]fluoro-6-nitroquipazine (1-2 Ci/mumol or 37-72 GBq/mumol) could be obtained in 70-80 min starting from a 550-650 mCi (20.3-24.0 GBq) aliquot of a cyclotron [F-18]F- production batch (2.7-3.8% non decay-corrected yield based on the starting [F-18]fluoride). Ex vivo studies (biodistribution in rat), as well as PET imaging (in monkey) demonstrated that 5-[(18)]fluoro-6-nitroquipazine ([F-18]-1d) readily crossed the blood brain barrier and accumulated in the regions rich in 5-HT transporter (frontal-and posterial cortex, striata). However, the low accumulation of the tracer in the thalamus (rat and monkey) as well as the comparable displacement of the tracer observed with both citalopram, a reference 5-HT re-uptake inhibitor and maprotiline, a norepinephrine re-uptake inhibitor (rat), indicate that 5-[F-18]fluoro-6-nitroquipazine ([F-18]-1d) does not have the suggested potential for PFT imaging of the serotin transporter (SERT). (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(02)00098-6

文献信息

• II. Synthesis and Biological Evaluation of Some Bioisosteres and Congeners of the Antitumor Agent, 2-{4-[(7-Chloro-2-quinoxalinyl)oxy]phenoxy}propionic Acid (XK469)
  作者：Stuart T. Hazeldine、Lisa Polin、Juiwanna Kushner、Kathryn White、Nicole M. Bouregeois、Brianna Crantz、Eduardo Palomino、Thomas H. Corbett、Jerome P. Horwitz

  DOI：10.1021/jm0200097

  日期：2002.7.1

  (21a-g) ring systems. The synthetic approach to each of the bioisosteres of 1 utilized the methodology developed in previous work (see Hazeldine, S. T.; Polin, L.; Kushner, J.; Paluch, J.; White, K.; Edelstein, M.; Palomino, E.; Corbett, T. H.; Horwitz, J. P. Design, Synthesis, and Biological Evaluation of Analogues of the Antitumor Agent 2-(4-[(7-Chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469)

  XK469（1）是我们实验室中评估的最高度和最广泛活性的抗肿瘤药物之一。随后的开发研究导致（R）-（+）1（NSC 698215）进入1期临床试验（NIH UO1-CA62487）。1的抗肿瘤作用机理尚待阐明，这促使人们不断努力拟订1的药效学模式。本研究的重点是对喹喔啉部分中基于拓扑的生物等位替代物进行合成和生物学评估的策略。铅化合物（1）由喹唑啉（4a-d），1,2,4-苯并三嗪（12a-18b）和喹啉（21a-g）环系统合成。对每个1的生物等排体的合成方法都采用了先前工作中开发的方法（请参见ST的Hazeldine； L。的Polin； J。的Kushner； J。的Paluch； J。的White； K.Edelstein； M。的Palomino，E .; TH，Corbett；Horwitz，JP设计，合成和抗肿瘤药2-（4-[（7-氯-2-喹喔啉基）氧基]苯氧基）丙酸（XK469）类似物的生物学评估。J
• PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20180086747A1

  公开（公告）日：2018-03-29

  The present application provides the compounds of formula I or IA or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein s, t, m, n, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are as described herein.

  本申请提供了化合物I或IA的化学式，或其药用可接受盐、异构体、互变异构体或其混合物，其中s、t、m、n、R1、R2、R3、R4、R5、R6和R7如本文所述。
• GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO
  申请人：Beaton Graham

  公开号：US20100152207A1

  公开（公告）日：2010-06-17

  GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure, wherein R 1a , R 1b , R 1c , R 1d , R 2 , R 2a , and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

  本发明揭示了GnRH受体拮抗剂，其在治疗男性和女性的多种性激素相关疾病中具有实用性。本发明的化合物具有以下结构，其中R1a，R1b，R1c，R1d，R2，R2a和A的定义如本文所述，包括立体异构体，酯类，溶剂合物和其药学上可接受的盐。本发明还揭示了含有本发明化合物与药学上可接受的载体的组合物，以及与其相关的方法，用于在需要的受试者中对抗促性腺激素释放激素。
• Novel organic electroluminescent compounds and organic electroluminescent device using the same
  申请人：Gracel Display Inc.

  公开号：EP2085450A1

  公开（公告）日：2009-08-05

  The present invention relates to novel organic electroluminescent compounds exhibiting high luminous efficiency, and organic electroluminescent devices comprising the same. The novel organic electroluminescent compounds according to the invention are represented by Chemical Formula (1) :

  本发明涉及具有高发光效率的新型有机电致发光化合物，以及包含这些化合物的有机电致发光器件。根据本发明的新型有机电致发光化合物由化学式（1）表示：
• Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
  申请人：Neurocrine Biosciences, Inc.

  公开号：US10336769B2

  公开（公告）日：2019-07-02

  GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R1c, R1d, R2, R2a, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

  本发明公开了 GnRH 受体拮抗剂，可用于治疗男性和女性的各种性激素相关疾病。本发明的化合物具有如下结构： 其中 R1a、R1b、R1c、R1d、R2、R2a 和 A 如本文所定义，包括其立体异构体、酯类、溶剂和药学上可接受的盐类。此外，还公开了含有本发明化合物与药学上可接受的载体结合的组合物，以及有关使用其在有需要的受试者体内拮抗促性腺激素释放激素的方法。